Business
Initiation of Research Coverage
Initiation of Research Coverage.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\nREACH - non-regulatory announcement\n26 June 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nInitiation of research coverage by Singer Capital Markets\n \nSolvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, is pleased to announce that Singer Capital Markets (\"Singers\") has today initiated equity research coverage (the \"Initiation Note\") on the Company.\nThe Initiation Note, titled \"Psyching up for success\", has been authored by Dr. Karl Keegan, Head of Life Sciences Research at Singers.\nThe research note is currently available to eligible institutional investors and will be made publicly available via Singers next week.\nEnquiries:\n\nSolvonis Therapeutics plc\nAnthony Tennyson, CEO & Executive Director\[email protected]\n\nAllenby Capital Limited (Financial Adviser and Joint Broker)\nNick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)\nGuy McDougall (Sales & Corporate Broking)\n+44 (0) 20 3328 5656\n\nSinger Capital Markets (Joint Broker)\nPhil Davies\n+44 (0) 20 7496 3000\n\nAbout Solvonis Therapeutics plc\n \nSolvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.\n \nThe Company's programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions which the Company estimates affect over 60 million people across the UK, US, and EU4. Its lead asset, SVN‑001, is currently in Phase 3 for severe AUD in Europe and the UK. SVN‑002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD programme, SVN‑SDN‑014, leveraging novel serotonin, dopamine, and noradrenalin modulators designed to enhance pro-social behaviour and long-term outcomes.\n \nIn addition, Solvonis is advancing an AI-supported discovery platform built on a proprietary CNS compound library, with initial focus on depression and stimulant use disorders.\n \nWith a capita...